Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Concord Biotech's share price for the quarter that ended in Jun. 2026 was ₹1280.2. Concord Biotech's Shares Outstanding (EOP) for the quarter that ended in Jun. 2026 was 105 Mil. Therefore, Concord Biotech's market cap for the quarter that ended in Jun. 2026 was ₹133,929 Mil.
Concord Biotech's quarterly market cap
declined
from Dec. 2025 (₹140,771 Mil) to Mar. 2026 (₹106,541 Mil) but then
increased
from Mar. 2026 (₹106,541 Mil) to Jun. 2026 (₹133,929 Mil).
Concord Biotech's annual market cap
increased
from Mar. 2024 (₹159,100 Mil) to Mar. 2025 (₹175,818 Mil) but then
declined
from Mar. 2025 (₹175,818 Mil) to Mar. 2026 (₹106,541 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Concord Biotech's Enterprise Value for Today is ₹160,112 Mil.
Concord Biotech (NSE:CONCORDBIO) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Concord Biotech Market Cap Related Terms
Concord Biotech Market Cap Historical Data
* Premium members only.
The historical data trend for Concord Biotech's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:CONCORDBIO vs VRTX, REGN, RVMD: Market Cap Comparison
For the Biotechnology subindustry, Concord Biotech's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Concord Biotech Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Concord Biotech's Market Cap distribution charts can be found below:
* The bar in red indicates where Concord Biotech's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Concord Biotech's Market Cap for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Concord Biotech (NSE:CONCORDBIO) has a Market Cap of ₹164,174 Mil as of Aug. 22, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Concord Biotech and its competitors. According to the industry distribution chart, Concord Biotech ranks #209 out of 1422 companies in the Biotechnology industry, placing it in the top 14.7%.
Is Concord Biotech's Market Cap too high?
Concord Biotech's current Market Cap is ₹164,174 Mil. Based on the distribution chart, Concord Biotech ranks #209 out of 1422 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Concord Biotech has a GF Score™ of 89/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Concord Biotech's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Concord Biotech ranks #209 out of 1422 companies for Market Cap. This places Concord Biotech in the top 15% of its industry — outperforming the majority of peers. The industry median Market Cap is 122.48. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 122.48, based on 1,422 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Concord Biotech and its competitors. For the Biotechnology industry, the median Market Cap is 122.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Concord Biotech's current Market Cap is ₹164,174 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Concord Biotech stock overvalued right now?
Based on GuruFocus' analysis, Concord Biotech (NSE:CONCORDBIO) is currently considered Fairly Valued. The stock's GF Value™ is ₹1,681.38, compared to a current price of ₹1,571.30 — trading 6.5% below its estimated fair value. The current Market Cap is ₹164,174 Mil. Concord Biotech's overall GF Score™ is 89/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Concord Biotech (NSE:CONCORDBIO), the current Market Cap is ₹164,174 Mil as of Aug. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Concord Biotech (NSE:CONCORDBIO) Overvalued in 2026?
Based on GuruFocus' analysis, Concord Biotech stock appears to be undervalued.
The current stock price of ₹1,571.30 is trading 6.5% below its estimated GF Value™ of ₹1,681.38.
GuruFocus considers Concord Biotech to be Fairly Valued.
Key valuation signals for NSE:CONCORDBIO:
Market Cap: ₹164,174 Mil
GF Value™: ₹1,681.38 vs. price of ₹1,571.30 (6.5% below fair value)
No single metric tells the full story. See the NSE:CONCORDBIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Concord Biotech Ltd is a research and development-driven biopharma company that manufactures Active Pharmaceutical Ingredients (API) through fermentation and semi-synthetic process and finished formulations. It is mainly engaged in the business of manufacturing and trading in pharmaceutical products. Geographically Company operates in two segments within India and outside India, having majority revenue from India.
89GF Score
Get the complete analysis for NSE:CONCORDBIO
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:CONCORDBIO has been successfully added to your 
